Industry Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Outperform the Market" and is maintained [1] Core Insights - The retail pharmacy industry is undergoing accelerated consolidation, with a significant reduction in the number of stores, leading to increased concentration benefiting leading players [4][15] - The number of retail pharmacies in China has decreased by nearly 20,000 since the fourth quarter of 2024, with a net reduction of 8,800 stores in the third quarter of 2025 alone [15][21] - Leading pharmacies are expected to see profit margins improve in 2026 due to operational optimizations and cost control measures [5][21] - The innovation drug sector is currently in a correction phase, but the maturation of clinical data is expected to drive future market performance [7][25] - The medical device sector is showing signs of recovery, with leading companies reporting improved performance in the third quarter of 2025 [29][30] Summary by Sections Industry Overview - The closing index for the pharmaceutical and biotechnology sector is 8084.61, with a 52-week high of 9323.49 and a low of 6764.34 [1] Recent Market Performance - The A-share pharmaceutical and biotechnology sector fell by 2.06% in the last week of December 2025, underperforming the CSI 300 index by 1.47 percentage points [6][22] - The retail pharmacy sector experienced a decline of 4.11% during the same period [22] Retail Pharmacy Insights - The retail pharmacy industry is seeing a rapid exit of smaller players, with a focus on consolidating market share among leading pharmacies [15][37] - The implementation of drug traceability codes is expected to further increase industry concentration by raising operational costs for smaller pharmacies [20] Innovation Drug Sector - The innovation drug sector is experiencing a correction, but the maturation of clinical data is anticipated to be a key driver for future performance [7][25] - Companies with stable business development (BD) expectations are recommended for investment, including Innovent Biologics and 3SBio [26] Medical Device Sector - The medical device industry is expected to benefit from improved procurement processes and a reduction in the pressure from centralized procurement [29][30] - Leading companies are showing signs of recovery, with Q3 performance improving compared to earlier in the year [29] Traditional Chinese Medicine - The traditional Chinese medicine sector is under pressure but is expected to benefit from policies favoring essential medicines and inventory clearance [34][36]

Core Viewpoint - Guangshengtang (300436.SZ) announced that its subsidiary, Guangsheng Zhonglin, has received a project approval notification for a national science and technology major project focused on the prevention and control of emerging infectious diseases, specifically for the research of new combined treatment plans for chronic hepatitis B clinical cure [1] Group 1 - The project aims to explore new combined treatment plans to improve the clinical cure rate of hepatitis B [1] - Guangsheng Zhonglin is responsible for research tasks one and three, utilizing the innovative hepatitis B drugs GST-HG131, GST-HG141, and combination therapies as research medications [1] - This project affirms the company's technological innovation capabilities and research and development strength in the field of hepatitis B treatment, highlighting its core competitiveness in related areas [1]

Group 1 - The Hong Kong Technology ETF (513020) rose over 4.2% on January 5, indicating a recovery momentum in the technology sector [1] - Huatai Securities noted that the current market sentiment and liquidity environment in Hong Kong are favorable, increasing the probability of successful investments in Hong Kong stocks [1] - The technology sector is expected to have room for growth under the conditions of liquidity easing and capital recovery, with a focus on fundamentals, industry prosperity, and profitability in 2026 [1] Group 2 - The Hong Kong Technology Index has outperformed the Hang Seng Technology Index, particularly in sectors like new energy vehicles, innovative pharmaceuticals, and semiconductors, with a cumulative return of 256.46% from the end of 2014 to October 2025, compared to 96.94% for the Hang Seng Technology Index [2] - The Hong Kong Technology ETF tracks the Hong Kong Technology Index (931573), which includes core assets in the technology sector such as internet, semiconductors, innovative pharmaceuticals, and new energy vehicles [1]

Core Viewpoint - The Chinese asset market is experiencing a strong start in 2026, with significant gains in both A-shares and Hong Kong stocks, driven by favorable monetary policies and sector-specific growth, particularly in pharmaceuticals and technology [1][24]. A-Share Market Summary - A-shares opened strongly, with the ChiNext Index rising by 2.85% and the Shanghai Composite Index surpassing 4000 points, achieving a record 12 consecutive days of gains, the longest streak since 1993, with trading volume exceeding 2.5 trillion yuan [1][24]. - The medical and healthcare sectors showed remarkable performance, with the Medical ETF (512170) increasing by 5.29%, marking its largest single-day gain since October 2024, and surpassing five key moving averages [4][26]. - The "AI twins" in the technology sector also performed well, with the Sci-Tech AI ETF (589520) rising by 4.74%, and the ChiNext AI ETF (159363) gaining over 3% to reach a new high since its listing [1][24]. Hong Kong Market Summary - The Hong Kong market also opened positively, with the Hang Seng Index rising by 2.76% and the Hang Seng Tech Index increasing by 4% on January 2, continuing to rise on January 5 [1][24]. - The Hong Kong Stock Connect Innovation Drug ETF (520880) surged by 5.42%, achieving its largest single-day gain since its launch in July 2025, with a trading volume of 5.09 billion yuan, reflecting a 263% increase from the previous day [4][28]. - The Hong Kong medical sector saw strong performance, particularly in the innovation drug segment, with 35 out of 37 covered stocks closing in the green, including notable gains from companies like InnoCare Pharma and Rongchang Bio [4][28]. Sector-Specific Insights - The brain-computer interface concept is gaining traction, with significant stock price increases in related companies, indicating a potential for substantial market growth in this area [6][28]. - The approval of 76 innovative drugs in China in 2025 set a historical record, with total transaction amounts exceeding 130 billion USD, highlighting the country's growing influence in the global pharmaceutical market [8][30]. - The technology sector, particularly in AI and semiconductor industries, is expected to continue its upward trajectory, supported by favorable policies and increasing foreign investment [1][24][15]. ETF Performance Overview - The Medical ETF (512170) recorded a trading volume of 11.66 billion yuan, a 211% increase from the previous trading day, reflecting strong investor interest in the healthcare sector [4][26]. - The Hong Kong Information Technology ETF (159131), focusing on the chip industry, rose by 3.63%, with a trading volume of 81.3 million yuan, indicating robust market activity in technology stocks [1][15]. Future Outlook - Analysts predict that the combination of domestic and international monetary policy easing will lead to continued net inflows of foreign and southbound capital, enhancing the profitability of Hong Kong-listed companies [1][24]. - The A-share market is expected to maintain its upward trend, driven by positive macroeconomic policies and a focus on technological innovation as a key driver for growth in 2026 [1][24].

Group 1 - The core viewpoint is that the pharmaceutical and biotechnology industry is entering a critical phase of innovation realization and global expansion, with a potential performance inflection point and valuation reshaping expected by 2026 [1] - The industry is focusing on next-generation innovative therapies represented by ADCs, bispecific/multispecific antibodies, cell and gene therapies, and small nucleic acids [1] - The impact of centralized procurement in the medical device sector is diminishing, and domestic high-end technology breakthroughs, along with rapid growth in international markets, are expected to lead to performance recovery for companies [1] Group 2 - In the chemical pharmaceutical sector, China's innovative drugs account for 30% of the global R&D pipeline, particularly leading in ADCs, bispecific antibodies, and cell therapies, with license-out transaction amounts exceeding $100 billion, indicating enhanced international competitiveness [1] - The overall valuation of the industry remains at historical lows, with innovation-driven and international expansion themes expected to dominate structural opportunities [1] - The ETF tracking the innovative pharmaceutical index focuses on innovative companies in biopharmaceuticals, chemical pharmaceuticals, and traditional Chinese medicine, aiming to reflect the overall performance of China's pharmaceutical industry's innovation development [1]

Market Performance - The three major A-share indices collectively rose in the morning session, with the Shanghai Composite Index increasing by 1.07% and returning to the 4000-point level, the Shenzhen Component Index rising by 1.87%, and the ChiNext Index up by 2.15% [1] - The total trading volume in the Shanghai and Shenzhen markets reached 1.6489 trillion yuan, an increase of 324 billion yuan compared to the previous day [1] - Over 4000 individual stocks in the market experienced gains [1] Sector Performance - Insurance stocks led the gains, while sectors such as brain-computer interfaces and innovative pharmaceuticals saw a surge in limit-up trading [1] - The semiconductor industry chain experienced a significant breakout, with AI applications and commercial aerospace themes also being active [1] - The Hainan Free Trade Zone, stablecoins, and oil sectors faced adjustments [1] ETF Performance - The semiconductor industry chain saw a notable increase, with the Huatai-PB Fund's China-Korea Semiconductor ETF rising by 6.52% [1] - In the Hong Kong stock market, the innovative pharmaceutical sector rebounded strongly, with the Fortune and Huatai-PB Fund's Hong Kong Stock Connect Medical ETF increasing by 6.21% and 5.92%, respectively [1] - Insurance stocks also led in the ETF space, with the GF Fund's Hong Kong Stock Connect Non-Bank ETF rising by 5.25% [1] Declining Sectors - The tourism sector declined, with two tourism ETFs dropping by 2% [1] - The oil and gas sector also saw declines, with the oil and gas ETFs from Huatai-PB falling by 1% and 0.87%, respectively [1]

Core Viewpoint - The biopharmaceutical industry in China experienced a volatile year in 2025, with significant growth in the first half followed by a sharp decline in the latter half, indicating a restructuring of the underlying logic of the industry [1][2][28]. Group 1: Industry Performance - The innovative drug sector saw explosive growth in the first half of 2025, with the China Innovation Drug Index rising by 13.43% and the Hong Kong Innovation Drug Index increasing by 60% [1][27]. - By December 28, 2025, the Hong Kong Innovation Drug Index had dropped over 20% since September, with many unprofitable biotech companies experiencing declines of over 40% [1][27]. Group 2: Policy Support - In 2025, the policy environment for biopharmaceuticals in China evolved to integrate national and local support, creating a comprehensive system for innovative drug development [4][30]. - Key policy initiatives included the release of measures to support innovative drug development, focusing on research support, inclusion in insurance, and clinical application [4][30]. - The introduction of a 30-day expedited review process for innovative drug clinical trial applications was implemented to enhance efficiency [4][30]. Group 3: Technological Advancements - The integration of AI in drug development accelerated in 2025, with AI tools becoming standard in pharmaceutical research and development [14][39]. - AI-driven companies like Insilico Medicine achieved significant milestones, including the rapid progression of drug candidates through clinical trials [14][40]. Group 4: Payment System Changes - The payment landscape for innovative drugs shifted from a focus on the lowest price to a more balanced approach that considers quality and reasonable pricing [16][42]. - The introduction of a commercial health insurance directory for innovative drugs marked a significant development, allowing for better access and affordability for patients [19][45]. Group 5: Business Development Transactions - The business development (BD) landscape in the innovative drug sector transitioned from a phase of enthusiasm to a more rational evaluation of value [22][48]. - By the end of 2025, the total amount of overseas licensing agreements in China's innovative drug sector exceeded $130 billion, setting a historical record [50]. - However, market reactions to BD announcements became more subdued, with significant stock price declines following major deals, indicating a reassessment of the quality and sustainability of such transactions [50][51].

Group 1 - The core point of the news is that Shanghai Haihe Pharmaceutical has been included in the "Star Plan" for the development of pediatric anti-tumor drugs, highlighting its strength in small molecule innovative drug research and development [1][2] - CYH33, a selective PI3Kα inhibitor, targets rare diseases such as PIK3CA-related overgrowth spectrum (PROS) and PIK3CA-related vascular malformations (PRVM), addressing a significant treatment gap for patients [2] - The inclusion of CYH33 in the Star Plan reflects the company's long-term commitment to small molecule innovative drug development, following previous successes with other innovative drugs [2][3] Group 2 - Haihe Pharmaceutical is advancing its value in the market through a comprehensive approach that includes research, clinical trials, commercialization, and internationalization [3] - The innovative drug industry is undergoing structural adjustments, and companies with core technologies and clear clinical value are better positioned to succeed in a competitive environment [3] - The ongoing clinical trials, expansion into overseas markets, and the launch of more pipeline products are expected to drive growth for Haihe Pharmaceutical and contribute to the overall value increase for the Huayi family [3]

2026年首个交易日，A股收获开门红，三大指数集体收涨，截至收盘，沪指报4023.42，涨1.38%，深成指报13828.63，涨2.24%，创业板指报3294.55，涨 2.85%，全市成交额25672亿元，超4100只个股上涨。 杨德龙认为，支持本轮牛市的逻辑未变，包括政策支持、居民储蓄大转移以及中国在科技创新方面的突破，大幅提升了外资对中国经济的信心。同时，美 联储继续处于降息周期，美元指数回落推动人民币升值，将吸引更多外资流入人民币资产，推动资产价值重估。 同时，A股市场通常有"春季攻势"的规律，1月份往往是全年信贷投放最多的月份，规模一般在3万亿至4万亿元左右，有助于部分资金进入资本市场，成 为市场的增量资金。一季度也是上市公司业绩披露的空窗期，有利于资金投向具备题材和估值弹性的科技板块。目前春季行情已经开启，大盘延续跨年度 走势，杨德龙也建议投资者保持信心和耐心。 银河证券也指出，假期期间港股市场与人民币汇率走强表现有助于提振投资者信心，A股市场或将延续结构性行情。后续上行节奏还要观察政策预期与产 业趋势突破，在上述因素支撑下，春季躁动行情可能提前开启。同时，仍需关注海外地缘风险等不确定性因素的短 ...

Core Viewpoint - The A-share market experienced a strong opening on the first trading day of the new year, with significant gains across major indices and a notable increase in trading volume [1][6]. Market Performance - On January 5, the Shanghai Composite Index rose by 1.38%, reclaiming the 4000-point mark, marking a 12-day consecutive rise, the longest since March 1992 [1][3]. - The Shenzhen Component Index increased by 2.24%, the ChiNext Index by 2.85%, and the Northbound 50 Index by 1.80% [1]. - Total trading volume across the Shanghai, Shenzhen, and North exchanges reached 25,672 billion yuan, an increase of 5,015 billion yuan compared to the previous trading day [1]. Historical Context - The 12-day consecutive rise of the Shanghai Composite Index from December 17, 2025, to January 5, 2026, set a new record since March 1992, where previous records included three instances of 11 consecutive days [3][4]. Sector Highlights - The brain-computer interface sector saw a surge, with nearly 30 stocks, including BeiYikang and MeiHao Medical, hitting the daily limit [4]. - Innovative drug concept stocks collectively surged, with GuanHao Biological reaching a 20% limit up, indicating sustained interest in this sector [4]. - The insurance sector performed strongly, with Xinhua Insurance and China Pacific Insurance both reaching historical highs during the trading session [4]. - The storage chip sector also experienced significant gains, with stocks like JiangBolong and XiangNong Chip rising sharply, reflecting renewed momentum in the technology sector [4]. - Other sectors such as gaming, commercial aerospace, and military equipment also showed robust performance during the trading day [5].